| Name | Title | Contact Details |
|---|---|---|
James Bircher |
Chief Technical Operations Officer | Profile |
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.
So—MAT—us is derived from the Latin word `Somata`, the plural form of `Soma`, which are the cells of the body—free of germ cells. We take Somatus to mean “our healthy bodies”.
Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.
AltMed LLC is a fully integrated, science-based Florida company bringing compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabis.